Предиабет как междисциплинарная проблема: определение, риски, подходы к диагностике и профилактике сахарного диабета 2 типа и сердечно-сосудистых осложнений

В Статье представлена резолюция совета экспертов по существующим проблемам и пути их решения в отношении раннней диагностики и терапии начальных проявлний нарушений обмена углеводов (предиабета), Показана роль немедикаментозной и медикаментозной терапии. Обозначены возможности медикаментозной терапии предиабета с помощью метформина

1. Authors/Task Force Members, Rydén L, Grant PJ, et al. ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013 Oct;34(39):3035-87. doi:10.1093/eurheartj/eht108.

2. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabet Med. 2007 May;24(5):451-63. doi:10.1111/j.1464-5491.2007.02157.x.

3. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-81. doi:10.1093/eurheartj/ehw106.

4. Кардиоваскулярная Профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;(6):7-122. doi:10.15829/1560-4071-2018-6-7-122.

5. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes — 2018. Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27. doi:10.2337/dc18-S002.

6. The International Expert Committee. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care. 2009 Jul;32(7):1327-34. doi:10.2337/dc09-9033.

7. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. 2017; 20,1S:1-121. doi:10.14341/DM20171S8.

8. Dedov I, Shestakova M, Galstyan G, et al. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Res Clin Pract. 2016 May;115:90-5. doi:10.1016/j.diabres.2016.02.010.

9. Симонова Г. И., Мустафина С. В., Печенкина Е. А. Распространённость метаболического синдрома в Сибири: популяционное исследование в г. Новосибирске. БЮЛЛЕТЕНЬ СО РАМН. 2011;31(5):100-6.

10. 2017 IDF clinical practice recommendations for managing type 2 diabetes in primary care. https://www.idf.org/e-library/guidelines/128-idf-clinical-practice-recommendations-formanaging-type-2-diabetes-in-primary-care.html.

11. Diabetes Canada Clinical Practice Guidelines Expert Committee, Ekoe JM, Goldenberg R, Katz P. Screening for Diabetes in Adults. Can J Diabetes. 2018 Apr;42 Suppl 1:S16-S19. doi:10.1016/j.jcjd.2017.10.004.

12. NICE 2017 Type 2 diabetes: prevention in people at high risk nice.org.uk/guidance/ph38.

13. Zhang X, Gregg EW, Williamson DF, et al. A1C Level and Future Risk of Diabetes: A Systematic Review. Diabetes Care. 2010 Jul;33(7):1665-73. doi:10.2337/dc09-1939.

14. Davis PJ, Liu M, Sherman S, Natarajan S et al. HbA1c, lipid profiles and risk of incident type 2 Diabetes in United States Veterans. PLoS One. 2018 Sep 13;13(9):e0203484. doi:10.1371/journal.pone.0203484.

15. Heianza Y, Arase Y, Fujihara K, et al. Screening for pre-diabetes to predict future diabetes using various cut-off points for HbA(1c) and impaired fasting glucose: the Toranomon Hospital Health Management Center Study 4 (TOPICS 4). Diabet Med. 2012 Sep;29(9):e279-85. doi:10.1111/j.1464-5491.2012.03686.x.

16. Warren B, Pankow JS, Matsushita K, et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2017 Jan;5(1):34-42. doi:10.1016/S2213-8587(16)30321-7.

17. Skriver MV, Borch-Johnsen K, Lauritzen T, et al. HbA1c as predictor of all-cause mortality in individuals at high risk of diabetes with normal glucose tolerance, identified by screening: a follow-up study of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION), Denmark. Diabetologia. 2010 Nov;53(11):2328-33. doi:10.1007/s00125-010-1867-9.

18. Vistisen D, Witte DR, Brunner EJ, et al. Risk of Cardiovascular Disease and Death in Individuals With Prediabetes Defined by Different Criteria: The Whitehall II Study. Diabetes Care. 2018 Apr;41(4):899-906. doi:10.2337/dc17-2530.

19. Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes. Primary Care: Clinics in Office Practice. 1999;26(4):771-90. doi:10.1016/s0095-4543(05)70130-5.

20. Шестакова М. В., Чазова И.Е, Шестакова Е. А. Российское многоцентровое скрининговое исследование по выявлению недиагностированного сахарного диабета 2 типа у пациентов с сердечно-сосудистой патологией. Сахарный диабет. 2016;19(1):24-9. doi:10.14341/DM7765.

21. Widmer RJ, Lerman A. Endothelial dysfunction and cardiovascular disease. Glob Cardiol Sci Pract. 2014 Oct 16;2014(3):291-308. doi:10.5339/gcsp.2014.43.

22. Eringa EC, Serne EH, Meijer RI, et al. Endothelial dysfunction in (pre)diabetes: Characteristics, causative mechanisms and pathogenic role in type 2 diabetes. Rev Endocr Metab Disord. 2013 Mar;14(1):39-48. doi:10.1007/s11154-013-9239-7.

23. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999 Sep;48(9):1856-62.

24. Stahrenberg R, Edelmann F, Mende M, et al. Association of glucose metabolism with diastolic function along the diabetic continuum Diabetologia. 2010 Jul;53(7):1331-40. doi:10.1007/s00125-010-1718-8.

25. Vlachopoulos C. Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and allcause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27. doi:10.1016/j.jacc.2009.10.061.

26. Park HE, Choi SY, Kim MK, et al. Cardio-ankle vascular index reflects coronary atherosclerosis in patients with abnormal glucose metabolism: Assessment with 256 slice multi-detector computed tomography. J Cardiol. 2012 Nov;60(5):372-6. doi:10.1016/j.jjcc.2012.07.005.

27. Açar B, Ozeke O, Karakurt M, et al. Association of Prediabetes With Higher Coronary Atherosclerotic Burden Among Patients With First Diagnosed Acute Coronary Syndrome. Angiology. 2019 Feb;70(2):174-80. doi:10.1177/0003319718772420.

28. Сумин А. Н., Безденежных Н. А., Безденежных А. В., и др. Предоперационный статус и госпитальные осложнения коронарного шунтирования у пациентов с предиабетом и сахарным диабетом 2 типа. Российский кардиологический журнал. 2018;(5):40-8. doi:10.15829/1560-4071-2018-5-40-48.

29. Matsushita K, Blecker S, Pazin-Filho A, et al. The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes. 2010 Aug;59(8):2020-6. doi:10.2337/db10-0165.

30. Kristensen SL, Preiss D, Jhund PS, et al. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016 Jan;9(1). pii: e002560. doi:10.1161/CIRCHEARTFAILURE.115.002560.

31. Приказ Министерства здравоохранения Российской Федерации от 15 ноября 2012 г. № 918н “Об утверждении Порядка оказания медицинской помощи больным с сердечно-сосудистыми заболеваниями”. https://www.rosminzdrav.ru/documents/9130-prikaz-ministerstva-zdravoohraneniyarossiyskoy-federatsii-ot-15-noyabrya-2012-g-918n-ob-utverzhdenii-poryadkaokazaniya-meditsinskoy-pomoschi-bolnym-s-serdechno-sosudistymi-zabolevaniyami.

32. Реестр профессиональных стандартов. Профессиональный стандарт “Врач-кардиолог”. http://profstandart.rosmintrud.ru/obshchiy-informatsionnyy-blok/natsionalnyy-reestrprofessionalnykh-standartov/reestr-professionalnykh-standartov/index.php?ELEMENT_ID=72087.

33. Реестр профессиональных стандартов. Профессиональный стандарт “Врач-лечебник (врач-терапевт участковый)”. http://profstandart.rosmintrud.ru/obshchiy-informatsionnyy-blok/natsionalnyy-reestr-professionalnykh-standartov/reestr-professionalnykh-standartov/index.php?ELEMENT_ID=66226.

34. American Diabetes Association. 5. Prevention or Delay of Type 2 Diabetes:Standards of Medical Care in Diabetes–2018. Diabetes Care. 2018 Jan;41(Suppl 1):S51- S54. doi:10.2337/dc18-S005.

35. Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med 2002;346:393-403. doi:10.1056/NEJMoa012512.

36. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015 Nov;3(11):866-75. doi:10.1016/S2213-8587(15)00291-0.

37. Инструкция по применению лекарственного препарата для медицинского применения Глюкофаж® П N014600/01.

38. Holman RR, Coleman RL, Chan JCN, et al. ACE Study Group. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-86. doi:10.1016/S2213-8587(17)30309-1.

39. Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing diabetes prevention study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2 014 Jun;2(6):474-80. doi:10.1016/S2213-8587(14)70057-9.

40. Goldberg RB, Aroda VR, Bluemke DA, et al. Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium. Circulation. 2017 Jul 4;136(1):52-64. doi:10.1161/CIRCULATIONAHA.116.025483.

41. Goldberg RB, Temprosa MG, Mather KJ, et al. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the Diabetes Prevention Program except in those who develop diabetes. Diabetes Care. 2014 Aug;37(8):2253-60. doi:10.2337/dc13-2471.

42. Mohan M, Al-Talabany S, McKinnie A, et al. Metformin regresses left ventricular hypertrophy in normotensive patients with coronary artery disease without type 2 diabetes mellitus — the met-remodel trial. Heart 2018;104:A6. doi:10.1136/heartjnl-2018-BCS.6.

43. Vitale C, Mercuro G, Cornoldi A, et al. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med. 2005 Sep;258(3):250-6. doi:10.1111/j.1365-2796.2005.01531.x.

44. Goldberg R, Temprosa M, Otvos J, et al. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2013 Oct;98(10):3989-98. doi:10.1210/jc.2013-1452.

45. Zhou L, Liu H, Wen X, et al. Effects of metformin on blood pressure in nondiabetic patients. J Hypertens. 2017 Jan;35(1):18-26. doi:10.1097/HJH.0000000000001119.